Literature DB >> 26433815

PD-L1 expression as a potential predictive biomarker.

Alberto Fusi1, Lucia Festino2, Gerado Botti2, Giuseppe Masucci3, Ignacio Melero4, Paul Lorigan5, Paolo A Ascierto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26433815     DOI： 10.1016/S1470-2045(15)00307-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  34 in total

1.  BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.

Authors:  J Wang; Y Jia; S Zhao; X Zhang; X Wang; X Han; Y Wang; M Ma; J Shi; L Liu
Journal:  Oncogene       Date:  2017-07-17       Impact factor: 9.867

Review 2.  Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?

Authors:  Susanne Lütje; Georg Feldmann; Markus Essler; Peter Brossart; Ralph A Bundschuh
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

3.  Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.

Authors:  Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Clin Exp Med       Date:  2018-01-23       Impact factor: 3.984

Review 4.  Promising clinical application of ctDNA in evaluating immunotherapy efficacy.

Authors:  Li Li; Jun Zhang; Xiaoyue Jiang; Qin Li
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

5.  Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.

Authors:  Xichen Zheng; Zhaoxu Fang; Xiaomei Liu; Shengming Deng; Pei Zhou; Xuexiang Wang; Chenglin Zhang; Rongping Yin; Haitian Hu; Xiaolan Chen; Yijie Han; Yun Zhao; Steven H Lin; Songbing Qin; Xiaohua Wang; Betty Ys Kim; Penghui Zhou; Wen Jiang; Qingyu Wu; Yuhui Huang
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

Review 6.  Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Authors:  Aric Colunga; Thomas Pulliam; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

Review 7.  Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?

Authors:  D-W Sun; L An; H-Y Huang; X-D Sun; G-Y Lv
Journal:  Clin Transl Oncol       Date:  2020-05-27       Impact factor: 3.405

8.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

9.  Enhanced gastric cancer growth potential of mesenchymal stem cells derived from gastric cancer tissues educated by CD4+ T cells.

Authors:  Rongman Xu; Xiangdong Zhao; Yuanyuan Zhao; Bin Chen; Li Sun; Changgen Xu; Bo Shen; Mei Wang; Wenrong Xu; Wei Zhu
Journal:  Cell Prolif       Date:  2017-10-22       Impact factor: 6.831

10.  Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Mahdi Zargar; Thomas McFarlane; Kelvin K W Chan; William W L Wong
Journal:  Oncologist       Date:  2017-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.